AGER and Alzheimer disease: The RAGE signaling pathway, a pivotal inducer of neuroinflammatory responses in AD, has been extensively targeted, leading to the development of small molecule antagonists designed to inhibit its activity.[45] Concurrently, employing sRAGE as a decoy receptor has emerged as a strategy to mitigate the effect of the RAGE pathway.[23, 46] However, a principal challenge with recombinant sRAGE‐based therapies is their limited capacity to traverse the BBB,[46a] a critical barrier for achieving neuroprotective outcomes in the brain.